CpG oligonucleotide as an adjuvant for the treatment of prostate cancer

David M Lubaroff1, Dev Karan

  • 1Department of Urology, University of Iowa, Iowa City, 52242, United States. david-lubaroff@uiowa.edu

Insights

Adding CpG motifs to an adenovirus-based prostate cancer vaccine (Ad/PSA) enhanced tumor destruction and survival but paradoxically reduced CD8+ T cell proliferation, despite CD8+ T cells mediating the therapeutic effect.

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Adenovirus-vectored vaccines expressing prostate-specific antigen (PSA) show promise for prostate cancer immunotherapy.
  • Pre-clinical models demonstrated Ad/PSA vaccine efficacy in prophylaxis but not in established tumors.
  • Enhancing anti-tumor immunity is crucial for developing effective prostate cancer immunotherapies.

Purpose of the Study:

  • To investigate the impact of immunostimulatory CpG motifs on Ad/PSA vaccine efficacy and immune responses.
  • To evaluate the role of CD8+ T cells in Ad/PSA plus CpG mediated anti-tumor activity.
  • To understand the mechanisms behind the observed immune response dichotomy.

Main Methods:

  • Adenovirus vectors expressing PSA (Ad/PSA) or ovalbumin (OVA) were used in pre-clinical mouse models.
  • CpG motifs were incorporated into the Ad/PSA vaccine formulation.
  • Tumor destruction, animal survival, and antigen-specific CD8+ T cell populations (number and activity) were assessed.
  • T cell proliferation assays were conducted to investigate immune cell dynamics.

Main Results:

  • Ad/PSA plus CpG vaccination enhanced in vivo tumor destruction and prolonged survival compared to Ad/PSA alone.
  • A significant decrease in the number and in vitro activity of antigen-specific CD8+ T cells was observed with Ad/PSA plus CpG.
  • Despite reduced CD8+ T cell numbers, these cells were confirmed to mediate the enhanced anti-tumor effects.
  • The reduction in CD8+ T cells was attributed to decreased proliferation of antigen-specific T cells.

Conclusions:

  • Immunostimulatory CpG motifs can enhance the therapeutic efficacy of Ad/PSA vaccines against prostate cancer.
  • A complex interplay exists between CpG adjuvantation, CD8+ T cell responses, and anti-tumor immunity.
  • Further research is needed to optimize vaccine strategies that balance potent anti-tumor effects with robust T cell immunity.

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...